NCT06213090 Patterns of Neurodevelopmental Disorders
| NCT ID | NCT06213090 |
| Status | Recruiting |
| Phase | — |
| Sponsor | Richard Frye |
| Condition | Neurodevelopmental Disorders |
| Study Type | OBSERVATIONAL |
| Enrollment | 1,000 participants |
| Start Date | 2024-02-01 |
| Primary Completion | 2030-12-31 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
This is an observational study. You will not receive an experimental treatment; researchers will collect data based on your existing condition or standard treatment.
This trial targets 1,000 participants in total. It began in 2024-02-01 with a primary completion date of 2030-12-31.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
The purpose of this study is to systematically evaluate the results of medical investigations to identify symptom and biological patterns and common etiologies of neurodevelopmental disorders.
Eligibility Criteria
Inclusion Criteria: Neurodevelopmental delays Clinical visit at an Rossignol Medical Center Exclusion Criteria: \-
Frequently Asked Questions
Who can join the NCT06213090 clinical trial?
This trial is open to participants of all sexes, studying Neurodevelopmental Disorders. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT06213090 currently recruiting?
Yes, NCT06213090 is actively recruiting participants. Visit ClinicalTrials.gov or contact Richard Frye to inquire about joining.
Where is the NCT06213090 trial being conducted?
This trial is being conducted at Phoenix, United States.
Who is sponsoring the NCT06213090 clinical trial?
NCT06213090 is sponsored by Richard Frye. The trial plans to enroll 1,000 participants.